$FATE
Fate Therapeutics Inc Stock $fate

$fate Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-K Financial Statement

#000156459017004614 Filed on March 16, 2017

Income Statement

Concept	2017 Q1	2016 Q4	2015 Q4
Revenue	$1.027M	$1.027M	$1.076M
YoY Change	-22.31%	-4.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.030M	$2.450M	$2.560M
YoY Change	16.54%	-4.3%	23.08%
% of Gross Profit
Research & Development	$7.970M	$6.230M	$5.430M
YoY Change	20.1%	14.73%	40.31%
% of Gross Profit
Depreciation & Amortization	$206.0K	$200.0K	$210.0K
YoY Change	-9.25%	-4.76%	61.54%
% of Gross Profit
Operating Expenses	$11.00M	$8.681M	$7.988M
YoY Change	19.05%	8.68%	34.41%
Operating Profit
YoY Change
Interest Expense	-$160.0K	-$290.0K	-$530.0K
YoY Change	-132.79%	-45.28%	82.76%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$10.13M	-$7.940M	-$7.450M
YoY Change	20.88%	6.58%	19.58%
Income Tax
% Of Pretax Income
Net Earnings	-$10.13M	-$7.940M	-$7.446M
YoY Change	20.88%	6.63%	19.46%
Net Earnings / Revenue	-985.98%	-773.13%	-692.01%
Basic Earnings Per Share
Diluted Earnings Per Share	-$244.7K	-$213.1K	-$259.4K
COMMON SHARES
Basic Shares Outstanding	41.39M	34.15M
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q4	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$82.30M	$92.10M	$64.80M
YoY Change	48.02%	42.13%	31.98%
Cash & Equivalents	$40.73M	$88.61M	$64.81M
Short-Term Investments	$41.70M	$3.500M
Other Short-Term Assets	$1.100M	$1.200M	$800.0K
YoY Change	10.0%	50.0%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$83.40M	$93.32M	$65.70M
YoY Change	47.35%	42.04%	31.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.700M	$1.579M	$2.200M
YoY Change	-15.0%	-28.23%	83.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$24.00K	$24.00K
YoY Change	0.0%	0.0%	-76.0%
Total Long-Term Assets	$1.900M	$1.725M	$2.258M
YoY Change	-9.52%	-23.6%	68.63%
TOTAL ASSETS
Total Short-Term Assets	$83.40M	$93.32M	$65.70M
Total Long-Term Assets	$1.900M	$1.725M	$2.258M
Total Assets	$85.30M	$95.05M	$67.96M
YoY Change	45.32%	39.86%	32.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.500M	$934.0K	$996.0K
YoY Change	25.0%	-6.22%	66.0%
Accrued Expenses	$4.700M	$3.957M	$2.439M
YoY Change	135.0%	62.24%	6.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.620M	$8.187M	$7.550M
YoY Change	-1.04%	8.44%	403.33%
Total Short-Term Liabilities	$16.90M	$15.19M	$13.44M
YoY Change	21.56%	12.99%	192.2%
LONG-TERM LIABILITIES
Long-Term Debt	$1.100M	$2.501M	$10.69M
YoY Change	-87.36%	-76.6%	-40.95%
Other Long-Term Liabilities	$3.500M	$4.200M	$5.800M
YoY Change	-35.19%	-27.59%	2800.0%
Total Long-Term Liabilities	$4.600M	$2.501M	$10.69M
YoY Change	-67.38%	-76.6%	-41.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.90M	$15.19M	$13.44M
Total Long-Term Liabilities	$4.600M	$2.501M	$10.69M
Total Liabilities	$21.50M	$17.69M	$24.13M
YoY Change	-23.21%	-26.69%	5.83%
SHAREHOLDERS EQUITY
Retained Earnings		-$175.8M	-$142.4M
YoY Change		23.5%
Common Stock		$249.0M	$180.4M
YoY Change		38.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$63.86M	$73.15M	$38.04M
YoY Change
Total Liabilities & Shareholders Equity	$85.30M	$95.05M	$67.96M
YoY Change	45.32%	39.86%	32.73%

Cashflow Statement

Concept	2017 Q1	2016 Q4	2015 Q4
OPERATING ACTIVITIES
Net Income	-$10.13M	-$7.940M	-$7.446M
YoY Change	20.88%	6.63%	19.46%
Depreciation, Depletion And Amortization	$206.0K	$200.0K	$210.0K
YoY Change	-9.25%	-4.76%	61.54%
Cash From Operating Activities	-$7.460M	-$7.550M	-$6.970M
YoY Change	2.9%	8.32%	13.33%
INVESTING ACTIVITIES
Capital Expenditures	$155.0K	-$40.00K	-$180.0K
YoY Change	-12.92%	-77.78%	-33.33%
Acquisitions
YoY Change
Other Investing Activities	-$38.22M	$6.020M	$0.00
YoY Change	136.36%
Cash From Investing Activities	-$38.38M	$5.980M	-$180.0K
YoY Change	134.88%	-3422.22%	-33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$2.011M
YoY Change	7.37%
Cash From Financing Activities	-2.170M	53.09M	-900.0K
YoY Change	25.43%	-5998.89%	-109.0%
NET CHANGE
Cash From Operating Activities	-7.460M	-7.550M	-6.970M
Cash From Investing Activities	-38.38M	5.980M	-180.0K
Cash From Financing Activities	-2.170M	53.09M	-900.0K
Net Change In Cash	-48.01M	51.52M	-8.050M
YoY Change	89.61%	-740.0%	-324.86%
FREE CASH FLOW
Cash From Operating Activities	-$7.460M	-$7.550M	-$6.970M
Capital Expenditures	$155.0K	-$40.00K	-$180.0K
Free Cash Flow	-$7.615M	-$7.510M	-$6.790M
YoY Change	2.52%	10.6%	15.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2501000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	29000
CY2016	dei	Trading Symbol TradingSymbol	FATE
CY2016Q2	dei	Entity Public Float EntityPublicFloat	43692948
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41386506
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64809000
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	3503000
CY2015Q4	fate	Repurchase Liability For Unvested Equity Awards Current RepurchaseLiabilityForUnvestedEquityAwardsCurrent	1000
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8187000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15187000
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	101000
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2829000
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4934000
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	1276000
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	799000
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	10688000
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	248957000
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	180393000
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-432000
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-33463000
CY2015	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-29992000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3184000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-6886000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	420000
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.05
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.18
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31754140
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25484262
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	50848000
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	142000
CY2014	fate	Adjustments To Additional Paid In Capital Repurchase Liability For Unvested Equity Awards AdjustmentsToAdditionalPaidInCapitalRepurchaseLiabilityForUnvestedEquityAwards	49000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2434000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	375000
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	375000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	28340000
CY2015	fate	Adjustments To Additional Paid In Capital Repurchase Liability For Unvested Equity Awards AdjustmentsToAdditionalPaidInCapitalRepurchaseLiabilityForUnvestedEquityAwards	44000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2400000
CY2015	fate	Incentive Bonuses Paid In Value IncentiveBonusesPaidInValue	97000
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	32149000
CY2015	fate	Common Stock Issued Value To Collaborative Partner CommonStockIssuedValueToCollaborativePartner	4580000
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	187000
CY2016	fate	Adjustments To Additional Paid In Capital Repurchase Liability For Unvested Equity Awards AdjustmentsToAdditionalPaidInCapitalRepurchaseLiabilityForUnvestedEquityAwards	1000
CY2016	fate	Common Stock Issued During Period Value Private Placement CommonStockIssuedDuringPeriodValuePrivatePlacement	28797000
CY2016	fate	Convertible Preferred Stock Issued During Period Value New Issues ConvertiblePreferredStockIssuedDuringPeriodValueNewIssues	36289000
CY2016	fate	Incentive Bonuses Paid In Value IncentiveBonusesPaidInValue	121000
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	881000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	687000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	496000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3184000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2400000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2434000
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	139000
CY2015	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	176000
CY2014	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	24000
CY2016	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-171000
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	492000
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	651000
CY2014	us-gaap	Paid In Kind Interest PaidInKindInterest	167000
CY2016	us-gaap	Straight Line Rent StraightLineRent	7000
CY2015	us-gaap	Straight Line Rent StraightLineRent	24000
CY2014	us-gaap	Straight Line Rent StraightLineRent	52000
CY2016	fate	Deferred Revenue Expense DeferredRevenueExpense	2401000
CY2015	fate	Deferred Revenue Expense DeferredRevenueExpense	-7335000
CY2014	fate	Stock Based Milestone Charges And Change In Fair Value Of Exchangeable Shares StockBasedMilestoneChargesAndChangeInFairValueOfExchangeableShares	375000
CY2014	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	3000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	381000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	107000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	146000
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1561000
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	477000
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	163000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-29823000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18397000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22419000
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	18000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	457000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1498000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	882000
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	19675000
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	16000000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4114000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1498000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-882000
CY2016	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	186000
CY2015	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	420000
CY2014	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	142000
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	32149000
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4580000
CY2014	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	20000000
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7689000
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1546000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	57737000
CY2014	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1750000
CY2014	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	26000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	35603000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	18366000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	23800000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	15708000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4935000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49101000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54036000
CY2016	us-gaap	Interest Paid InterestPaid	1067000
CY2015	us-gaap	Interest Paid InterestPaid	1353000
CY2014	us-gaap	Interest Paid InterestPaid	494000
CY2014	fate	Issuance Of Warrants In Connection With Long Term Debt IssuanceOfWarrantsInConnectionWithLongTermDebt	375000
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company’s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”). The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p></div>
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash, cash equivalents, and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits and investments are held. </p></div>
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2016Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2016Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2016Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2016Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2016	us-gaap	Revenue Recognition Milestone Method Factors RevenueRecognitionMilestoneMethodFactors	(i) persuasive evidence that an agreement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured.
CY2016	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	more than 50 percent
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18667458
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3246837
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2560082
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	3504000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	7547000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	7354000
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	7988000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-7779000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-7446000
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	3503000
CY2016	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2016	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5783000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5632000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4204000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3472000
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1505000
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	993000
CY2016Q4	fate	Accrued Clinical Trial Related Costs Current AccruedClinicalTrialRelatedCostsCurrent	1043000
CY2015Q4	fate	Accrued Clinical Trial Related Costs Current AccruedClinicalTrialRelatedCostsCurrent	446000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1409000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1000000
CY2016	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	37641
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10765000
CY2015Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18454000
CY2016Q4	fate	Debt Instrument Discount Non Current DebtInstrumentDiscountNonCurrent	7000
CY2015Q4	fate	Debt Instrument Discount Non Current DebtInstrumentDiscountNonCurrent	77000
CY2016Q4	fate	Long Term Debt Net Of Long Term Portion Of Debt Issuance Costs And Discounts LongTermDebtNetOfLongTermPortionOfDebtIssuanceCostsAndDiscounts	10758000
CY2015Q4	fate	Long Term Debt Net Of Long Term Portion Of Debt Issuance Costs And Discounts LongTermDebtNetOfLongTermPortionOfDebtIssuanceCostsAndDiscounts	18377000
CY2016Q4	fate	Long Term Debt Gross Current LongTermDebtGrossCurrent	8257000
CY2015Q4	fate	Long Term Debt Gross Current LongTermDebtGrossCurrent	7689000
CY2016Q4	fate	Debt Instrument Discount Current DebtInstrumentDiscountCurrent	70000
CY2015Q4	fate	Debt Instrument Discount Current DebtInstrumentDiscountCurrent	139000
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	1600000
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	2200000
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	500000
CY2016Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	100000
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1300000
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1200000
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	900000
CY2016	fate	Minimum Annual Payments To Maintain Licenses MinimumAnnualPaymentsToMaintainLicenses	300000
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	8757000
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4055000
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	12812000
CY2016Q4	fate	Long Term Debt Maturities Repayments Interest Included In Payments LongTermDebtMaturitiesRepaymentsInterestIncludedInPayments	547000
CY2016Q4	fate	Long Term Debt Maturities Additional Payments Due On Maturity LongTermDebtMaturitiesAdditionalPaymentsDueOnMaturity	1500000
CY2016Q4	fate	Unamortized Debt Discounts And Debt Issuance Cost UnamortizedDebtDiscountsAndDebtIssuanceCost	77000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1237000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2116000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2278000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2346000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2417000
CY2016Q4	fate	Operating Leases Future Minimum Payments Due In Six Years OperatingLeasesFutureMinimumPaymentsDueInSixYears	2489000
CY2016Q4	fate	Operating Leases Future Minimum Payments Due In Seven Years OperatingLeasesFutureMinimumPaymentsDueInSevenYears	1282000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	14165000
CY2016Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	9994000
CY2016Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	6171000
CY2016Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	2278000
CY2016Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	2346000
CY2016Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	2417000
CY2016Q4	fate	Contractual Obligation Due In Sixth Year ContractualObligationDueInSixthYear	2489000
CY2016Q4	fate	Contractual Obligation Due In Seventh Year ContractualObligationDueInSeventhYear	1282000
CY2016Q4	us-gaap	Contractual Obligation ContractualObligation	26977000
CY2016	us-gaap	Dividends Dividends	0
CY2016Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	76000
CY2015Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	159000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	58766000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47644000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58766000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47644000
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0
CY2016Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20456523
CY2015Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4884125
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11377000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10198000
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8800000
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2089000
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2226000
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1311000
CY2016	fate	Income Tax Reconciliation Permanent Tax Differences IncomeTaxReconciliationPermanentTaxDifferences	292000
CY2015	fate	Income Tax Reconciliation Permanent Tax Differences IncomeTaxReconciliationPermanentTaxDifferences	43000
CY2014	fate	Income Tax Reconciliation Permanent Tax Differences IncomeTaxReconciliationPermanentTaxDifferences	159000
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	968000
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	213000
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	426000
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	971000
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	594000
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	596000
CY2016	fate	Income Tax Reconciliation Reserve For Uncertain Tax Positions IncomeTaxReconciliationReserveForUncertainTaxPositions	2076000
CY2015	fate	Income Tax Reconciliation Reserve For Uncertain Tax Positions IncomeTaxReconciliationReserveForUncertainTaxPositions	1733000
CY2016	fate	Income Tax Reconciliation Tax Attribute Limitation IncomeTaxReconciliationTaxAttributeLimitation	54000
CY2015	fate	Income Tax Reconciliation Tax Attribute Limitation IncomeTaxReconciliationTaxAttributeLimitation	2727000
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-74000
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-37000
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-256000
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11121000
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3887000
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10378000
CY2016Q4	fate	Deferred Tax Assets Section59e Amortization DeferredTaxAssetsSection59eAmortization	17699000
CY2015Q4	fate	Deferred Tax Assets Section59e Amortization DeferredTaxAssetsSection59eAmortization	13042000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35049000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28963000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2175000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1274000
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1020000
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	921000
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1677000
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2494000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1222000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1109000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1329000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	491000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1820000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	374000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2624000
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	949000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3869000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2268000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1625000
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	32000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7730000
CY2016Q4	fate	Unrecognized Tax Benefits Resulting In Net Operating Loss And Tax Credit Carryforward UnrecognizedTaxBenefitsResultingInNetOperatingLossAndTaxCreditCarryforward	0
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2009Q1	fate	Defined Contribution Plan Minimum Age Of Employee DefinedContributionPlanMinimumAgeOfEmployee	P21Y
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1322000
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1027000
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1026000
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	1027000
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	9238000
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	9031000
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	9415000
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	8681000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-8377000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-8408000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-8737000
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-7940000
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	329000
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1026000
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	1076000
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	7324000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-7881000
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38

Files In Submission

Name	View Source	Status
0001564590-17-004614-index-headers.html	Edgar Link	pending
0001564590-17-004614-index.html	Edgar Link	pending
0001564590-17-004614.txt	Edgar Link	pending
0001564590-17-004614-xbrl.zip	Edgar Link	pending
fate-10k_20161231.htm	Edgar Link	pending
fate-20161231.xml	Edgar Link	completed
fate-20161231.xsd	Edgar Link	pending
fate-20161231_cal.xml	Edgar Link	unprocessable
fate-20161231_def.xml	Edgar Link	unprocessable
fate-20161231_lab.xml	Edgar Link	unprocessable
fate-20161231_pre.xml	Edgar Link	unprocessable
fate-ex211_152.htm	Edgar Link	pending
fate-ex231_9.htm	Edgar Link	pending
fate-ex311_11.htm	Edgar Link	pending
fate-ex321_6.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g2017031518182007540616.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FATE
Fate Therapeutics Inc Stock $fate

2017 Q1 Form 10-K Financial Statement

#000156459017004614 Filed on March 16, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE Fate Therapeutics Inc Stock $fate

2017 Q1 Form 10-K Financial Statement

#000156459017004614 Filed on March 16, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE
Fate Therapeutics Inc Stock $fate